EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials

Craig B H Surman iD, Daniel M Walsh

The Journal of Clinical Pharmacology · 2023-06 · 63 (6) · 640-653

DOI: 10.1002/jcph.2209 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 13.03.2023. Verfasst von Craig B H Surman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Research Program in ADHD and Related Disorders, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We sought to understand the effect of current treatments for attention deficit hyperactivity disorder (ADHD) on executive functioning deficits, which are often comorbid with ADHD, via a systematic analysis of adult ADHD treatment studies evaluating change in behavioral measures beyond the core symptoms of Diagnostic and Statistical Manual of Mental Disorders ADHD. The standardized mean difference for behavioral measures of executive functioning was determined from controlled trials of adults with ADHD and compared with effects on core ADHD symptoms. Several studies of atomoxetine revealed small to large standardized mean differences. Nonreplicated studies revealed small to medium effects for triple‐bead mixed amphetamine salts, lisdexamfetamine, and forms of cognitive behavioral therapy. Proportional effect versus core ADHD symptoms ranged from 0.78 to 1.16 for atomoxetine, and from 0.65 to 1.44 across all the studies. ADHD treatments have effects on executive functioning behavior beyond core ADHD symptoms in adults. Clinicians can measure and treat this morbidity using available clinical tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsAdultHumansAtomoxetine HydrochlorideAmphetamineLisdexamfetamine DimesylateExecutive Function

Stichwörter der Autor:innen

ADHDadultexecutive functiontreatment

Substanzen

Atomoxetine HydrochlorideAmphetamineLisdexamfetamine DimesylateCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Clinical and Research Program in ADHD and Related Disorders, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Craig B H Surman

Zitieren

APA

Surman, C. B. H., & Walsh, D. M. (2023). Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials. The Journal of Clinical Pharmacology, 63(6), 640-653. https://doi.org/10.1002/jcph.2209

Vancouver

Surman CBH, Walsh DM. Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials. The Journal of Clinical Pharmacology. 2023;63(6):640-653. doi:10.1002/jcph.2209

BibTeX
@article{Surman2023,
  author = {Surman, Craig B H and Walsh, Daniel M},
  title = {Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  volume = {63},
  number = {6},
  pages = {640--653},
  doi = {10.1002/jcph.2209}
}
Kostenlos starten →